Alpha Cancer Technologies (ACT) Announces Publication in Critical Reviews in Oncology/Hematology

June 13, 2024
Press Release
Toronto, Canada, June 12, 2024 — Alpha Cancer Technologies (ACT), a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunomodulation therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced that an article titled, “Comprehensive Approach to Cancer Immunotherapy – Simultaneous Targeting of Myeloid-derived Suppressor Cells and Cancer Cells with AFP Conjugates” was published in Critical Reviews in Oncology/Hematology. The full published article can be accessed using this link.